Crossmark

Structural insights into binding specificity, efficacy and bias of a β2AR partial agonist

Crossref DOI link: https://doi.org/10.1038/s41589-018-0145-x

Published Online: 2018-10-16

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Masureel, Matthieu

Zou, Yaozhong

Picard, Louis-Philippe

van der Westhuizen, Emma http://orcid.org/0000-0001-9165-8526
Mahoney, Jacob P.

Rodrigues, João P. G. L. M.

Mildorf, Thomas J.

Dror, Ron O.

Shaw, David E.

Bouvier, Michel http://orcid.org/0000-0003-1128-0100
Pardon, Els

Steyaert, Jan

Sunahara, Roger K. http://orcid.org/0000-0003-1702-8619
Weis, William I.

Zhang, Cheng http://orcid.org/0000-0001-9042-4007
Kobilka, Brian K.
License Information

Text and Data Mining valid from 2018-10-16
More Information

Article History

Received: 9 May 2018

Accepted: 6 September 2018

First Online: 16 October 2018

Change Date: 30 November 2018

Change Type: Correction

Change Details: In the version of this paper originally published, the structure for epinephrine shown in Figure 1a was redrawn with an extra carbon. The structure has been replaced in the HTML and PDF versions of the article. The original and corrected versions of the structure are shown below.

Competing interests

: The BRET-based biosensors used in the present study are licensed to Domain Therapeutics but are freely available from M.B. for noncommercial academic use. M.B. is the chair of the Scientific Advisory Board of Domain Therapeutics. B.K.K. is a cofounder of and consultant for ConfometRx.